BACKGROUND/ PURPOSE: A globally increasing trend of type 2 diabetes mellitus (DM), the rising prevalence of tuberculosis (TB) in many countries, and the emergence of multidrug-resistant TB (MDR-TB) in recent years pose a serious challenge for TB control. METHODS: We investigated pulmonary tuberculosis patients with and without type 2 DM (DMTB and TB, respectively) treated at the Chest Hospital, Taiwan, between November 2004 and October 2005. RESULTS: One hundred and ninety-two new patients (60 DMTB, 132 TB) were regularly treated for a full course (≥ 6 months) and prospectively followed for more than 1 year. The DMTB patients had more severe infections (far-advanced: 45.0%vs. 22.7%, p < 0.01), higher mycobacterial loads (sputum smear: 2.9 ± 1.3(+)vs. 1.9 ± 1.7(+), p < 0.01), higher treatment failure rates (17%vs. 2%, p < 0.01), and longer delayed clearance of mycobacteria than did the TB patients (2.5 ± 3.0 months vs. 1.6 ± 1.4 months, p < 0.01). After one year, three DMTB patients and one TB patient had MDR-TB (5.0%vs. 0.8%, p = 0.056). Bacterial genotyping revealed that the proportion of mycobacterial strains was not significantly different in DMTB and TB patients (Beijing strain: 46.7%vs. 40.6%, Non-Beijing strain: 53.3%vs. 59.4%, p = 0.632). CONCLUSION: DMTB patients have more severe TB infections, which require longer treatment and are more likely to develop MDR-TB than are patients with TB alone.
BACKGROUND/ PURPOSE: A globally increasing trend of type 2 diabetes mellitus (DM), the rising prevalence of tuberculosis (TB) in many countries, and the emergence of multidrug-resistant TB (MDR-TB) in recent years pose a serious challenge for TB control. METHODS: We investigated pulmonary tuberculosispatients with and without type 2 DM (DMTB and TB, respectively) treated at the Chest Hospital, Taiwan, between November 2004 and October 2005. RESULTS: One hundred and ninety-two new patients (60 DMTB, 132 TB) were regularly treated for a full course (≥ 6 months) and prospectively followed for more than 1 year. The DMTBpatients had more severe infections (far-advanced: 45.0%vs. 22.7%, p < 0.01), higher mycobacterial loads (sputum smear: 2.9 ± 1.3(+)vs. 1.9 ± 1.7(+), p < 0.01), higher treatment failure rates (17%vs. 2%, p < 0.01), and longer delayed clearance of mycobacteria than did the TB patients (2.5 ± 3.0 months vs. 1.6 ± 1.4 months, p < 0.01). After one year, three DMTBpatients and one TB patient had MDR-TB (5.0%vs. 0.8%, p = 0.056). Bacterial genotyping revealed that the proportion of mycobacterial strains was not significantly different in DMTB and TB patients (Beijing strain: 46.7%vs. 40.6%, Non-Beijing strain: 53.3%vs. 59.4%, p = 0.632). CONCLUSION:DMTBpatients have more severe TB infections, which require longer treatment and are more likely to develop MDR-TB than are patients with TB alone.
Authors: M J Magee; E Bloss; S S Shin; C Contreras; H Arbanil Huaman; J Calderon Ticona; J Bayona; C Bonilla; M Yagui; O Jave; J P Cegielski Journal: Int J Infect Dis Date: 2013-02-22 Impact factor: 3.623
Authors: Stijn W van Beek; Rob Ter Heine; Ron J Keizer; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson Journal: Clin Pharmacokinet Date: 2019-06 Impact factor: 6.447
Authors: M J Magee; R R Kempker; M Kipiani; N R Gandhi; L Darchia; N Tukvadze; P P Howards; K M V Narayan; H M Blumberg Journal: Int J Tuberc Lung Dis Date: 2015-06 Impact factor: 2.373
Authors: A K Hemanth Kumar; V Chandrasekaran; T Kannan; A Lakshmi Murali; J Lavanya; V Sudha; Soumya Swaminathan; Geetha Ramachandran Journal: Eur J Clin Pharmacol Date: 2016-09-20 Impact factor: 2.953
Authors: Anca Lelia Riza; Fiona Pearson; Cesar Ugarte-Gil; Bachti Alisjahbana; Steven van de Vijver; Nicolae M Panduru; Philip C Hill; Rovina Ruslami; David Moore; Rob Aarnoutse; Julia A Critchley; Reinout van Crevel Journal: Lancet Diabetes Endocrinol Date: 2014-09 Impact factor: 32.069